Status:
COMPLETED
Study of Flavocoxid (Limbrel) vs Naproxen in Subjects With Mod-Severe Osteoarthritis of the Knee
Lead Sponsor:
Primus Pharmaceuticals
Conditions:
Osteoarthritis
Eligibility:
All Genders
35-85 years
Phase:
NA
Brief Summary
Randomized, double-blind, placebo controlled parallel group, multi center study in subjects with moderate-severe osteoarthritis.
Detailed Description
This will be a randomized, double blind, placebo controlled, parallel group, multi-center study in subjects with moderate-severe OA. Subjects will be randomized to receive flavocoxid 250 mg bid, flavo...
Eligibility Criteria
Inclusion
- OA of the Knee
- K-L Grade 2-3
- Positive response to NSAIDS
Exclusion
- K-L grade 1 0r 4 OA of the knee
- History of GI Bleed within past 5 years
- Chronic bleeding disorder
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT00435292
Start Date
April 1 2006
End Date
December 1 2007
Last Update
October 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Primus Pharmaceuticals, Inc
Scottsdale, Arizona, United States, 85251